Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostate Cancer Metastatic × enzalutamide × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 83 Prostatic Neoplasms, Castration-Resistant 10 Neoplasms 7 Neoplasm Metastasis 7 Breast Neoplasms 7 Carcinoma, Non-Small-Cell Lung 4 Small Cell Lung Carcinoma 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Metastatic Castration-Resistant Prostate Cancer 3 Melanoma 3 mCRPC 2 Uterine Cervical Neoplasms 2 Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2 Prostate Adenocarcinoma 2 Metastatic Hormone-sensitive Prostate Cancer 2 Metastatic Hormone Sensitive Prostate Cancer 2 Metastatic Castration-resistant Prostate Cancer 2 Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2 Endometrial Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Hepatocellular 2 Bites and Stings 2 Adenocarcinoma 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Solid Tumor 1 Sleep Initiation and Maintenance Disorders 1 Salivary Cancer 1

Interventions

Radiosurgery 3 Prednisone 2 Docetaxel 2 Androgen Antagonists 2 Abiraterone Acetate 2 fludrocortisone acetate 1 enzalutamide 1 apalutamide 1 Standard of Care 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Pluvicto 1 Lutetium-177 1 Lutetium 1 Hydrocortisone 1 Gonadotropin-Releasing Hormone 1 Dexamethasone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06136624 2026-03-11

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡